Biogen Inc

IDP
204,50
0,90 (0,44%)
08 Mag 2024 - Chiuso
Dati in Tempo Reale
Borsa: Tradegate
Tipo: Azione Ordinaria
Valuta: EUR

Ultime notizie

Data Ora Fonte Titolo
25/4/202422:05GLOBEBiogen Receives Positive CHMP Opinion for TOFIDENCE™..
06/3/202413:30GLOBENew Biomarker Data Add Further Evidence Supporting the..
04/3/202422:15GLOBEBiogen Highlights New Data at the International Conference..
23/2/202413:00GLOBEBiogen’s QALSODY® (tofersen), the First Therapy to Treat..
12/2/202422:06GLOBEBiogen Received European Commission Approval for SKYCLARYS®..
31/1/202413:30GLOBEBiogen to Realign Resources for Alzheimer's Disease..
19/12/202313:30GLOBECentralized Marketing Authorizations of Generic Versions of..
15/12/202315:05GLOBECHMP Issues Positive Opinion for Biogen’s SKYCLARYS®..
14/12/202312:30GLOBEZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for..
06/11/202313:30GLOBEBiogen Appoints Monish Patolawala to its Board of Directors
25/10/202323:26GLOBEEisai Presents New LEQEMBI® (lecanemab-irmb) Investigational..
19/10/202313:30GLOBEBiogen to Present New Data at the Clinical Trials on..
26/9/202314:59GLOBEBiogen Completes Acquisition of Reata Pharmaceuticals
25/9/202307:02GLOBELEQEMBI® Intravenous Infusion (Lecanemab) Approved for the..
06/9/202313:30GLOBEBiogen Appoints Jane Grogan as Head of Research
05/8/202304:41GLOBEFDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral..
28/7/202313:05GLOBEBiogen to Acquire Reata Pharmaceuticals
20/7/202301:30GLOBEEisai Presents Latest Analysis of Lecanemab’s Effect on..
07/7/202302:00GLOBEFDA Grants Traditional Approval for LEQEMBI®..
12/6/202323:14GLOBEBiogen Announces Changes to Its Board of Directors
10/6/202300:45GLOBEFDA Advisory Committee Votes Unanimously to Confirm the..
16/5/202301:30GLOBEHealth Canada Accepts New Drug Submission for Lecanemab as..
Apertura: 204,60 Min: 201,70 Max: 205,00
Chiusura: 203,60

La tua Cronologia

Delayed Upgrade Clock

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network